JPRN-UMIN000014981招募中未知
Phase 2 study of afatinib in patients with previously treated advanced non-sq NSCLC haboring EGFR mutation - Phase 2 study of afatinib in patients with previously treated advanced non-sq NSCLC haboring EGFR mutation
Gunma University Graduate School of Medicine0 个研究点目标入组 55 人开始时间: 2014年8月28日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patient with serious disease condition (severe heart disease, interstitial pneumonia, uncontrollable hypertension, diabetes mellitus, etc) 2) Age 20-74 years old 3) Patients who have previously treated with EGFR-TKI 4) Platinum combination chemotherapy naive 5) Patient with much ascetic fluid, pleural effusion, cardiac effusion. 6) Patient with active infection 7) Considered as unfit to study drug administration by attending doctor according to clinical symptomatic olthalmic disorder 8) Pregnancy 9) Symptomatic brain metastases 10) Patient with active double cancer (Exclude disease free interval over 5 years and carcinoma in situ) 11) Patients who have exon 20 T790M 12) Considered as unfit to study drug administration by attending doctor according to clinical symptoms or laboratory abnormalities. 13) Considered to be interfere to the agreement or understanding the protocol by attening doctor. Other ineligible status judged by attending doctor.
研究者
相似试验
已完成
2 期
Phase II Study of First-Line Afatinib in Patients Aged 75 or Older With Advanced Lung Adenocarcinoma With EGFR MutationsElderly patients with NSCLC harboring sensitive EGFR mutationJPRN-UMIN000015834Osaka Lung Cancer Study Group38
进行中（未招募）
1 期
Afatinib and selumetinib in advanced KRAS mutant positive and PIK3CA wildtype non-small cell lung cancer and colorectal cancerPatients with histological or cytological proof of advanced KRAS mutant and PIK3CA wildtype non small cell lung cancer (NSCLC) and colorectal cancer (CRC). In part B: for which first-line treatment failed.MedDRA version: 21.1 Level: PT Classification code 10029520 Term: Non-small cell lung cancer stage IIIA System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10029521 Term: Non-small cell lung cancer stage IIIB System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10029515 Term: Non-small cell lung cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10029518 Term: Non-small cell lung cancer stage II System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001855-22-NLetherlands Cancer Institute- Antoni van Leeuwenhoek Hospital140
进行中（未招募）
2 期
EJ025Bon-sequamous non-small cell lung cancerJPRN-jRCTs021200005Maemondo Makoto35
进行中（未招募）
2 期
A phase 2 study of afatinib for NSCLC with uncommon EGFR mutation detected by NGSon-small cell lung cancer with uncommon EGFR mutaitonJPRN-jRCTs041190027Takahashi Toshiaki17
进行中（未招募）
1 期
Afatinib in combination with cetuximab in EGFR exon 20 insertion positive non-small-cell lung cancerEGFR exon 20 insertion positive non-small cell lung cancerMedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001521-97-NLStichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis37